
    
      Phase 1 study to assess the safety, preliminary efficacy of CD19 t-haNK and to determine the
      maximal tolerated dose and designate the recommended phase 2 dose in subjects with diffuse
      large B-cell lymphoma (DLBCL). The study will be conducted in 2 parts: part 1 will involve
      dose escalation and part 2 will involve expansion of the recommended phase 2 dose.
    
  